股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華康生物醫學控股有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08622 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.01 | HKD | | 10,000,000 | 本月底法 ...

自2025年8月29日起，经考虑提名委员会之建议，执行董事张玉静女士已被任命为董事会主席。其亦聘 任为授权代表及提名委员会主席，接替张先生的职务，以填补其辞任后留下的空缺。 华康生物医学(08622)发布公告，张曙光先生经与董事会讨论后，其为投放更多时间专注于公司之附属 公司的业务管理而非公司的执行职能，故已辞任公司执行董事;董事会主席;提名委员会主席及根据香港 联合交易所有限公司GEM证券上市规则第5.24条的授权代表，自2025年8月29日起生效。 ...

Group 1 - The core point of the article is the resignation of Mr. Zhang Shuguang from his positions as executive director, chairman of the board, and chairman of the nomination committee of Huakang Biomedical, effective from August 29, 2025, to focus on the management of the company's subsidiaries [1] - Ms. Zhang Yujing has been appointed as the new chairman of the board, authorized representative, and chairman of the nomination committee, effective from the same date, to fill the vacancy left by Mr. Zhang's resignation [1]

FF003G 香港聯合交易所有限公司 （香港交易及結算所有限公司的全資附屬公司） 監管表格 本資料報表列載若干有關上述在香港聯合交易所有限公司（「交易所」）GEM 上市的公司（「該公司」）的資料。該等資 料乃遵照香港聯合交易所有限公司《GEM 證券上市規則》（《GEM 上市規則》）的規定而提供，旨在向公眾提供有關該 公司的資料。該等資料將會在互聯網的 GEM 網頁展示。本資料報表不應視作有關該公司及╱或其證券的完整資料概要。 本報表的資料乃於 二零二五年八月二十九日 更新。 A. 一般資料 上市申請表格 G 表格 GEM 公司資料報表 香港交易及結算所有限公司及香港聯合交易所有限公司對本資料報表的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不對因本資料報表全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔 任何責任。 公司名稱: Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公司 證券代號 (普通股): 8622 保薦人名稱: 興業金融融資有限公司 執行董事 Zhang Chunguang (張春光) Poon Lai ...

(於開曼群島註冊成立之有限公司) (股份代號: 8622) 董事名單及其角色及職能 華康生物醫學控股有限公司之董事會（「董事會」）成員如下載列： 執行董事 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 M ： 相關董事委員會成員 董事會已成立三個委員會，而該等委員會的成員如下載列： | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 張玉靜女士 | | – | – | C | | 張春光先生 | | – | M | – | | 周國輝博士 | | M | M | M | | 王亞純女士 | | M | C | M | | 徐永得先生 | | C | – | M | 非執行董事 卜素博士 徐明博士 香港，二零二五年八月二十九日 獨立非執行董事 周國輝博士 王亞純女士 徐永得先生 附註： C ： 相關董事委員會主席 張玉靜女士（主席） 張春光先生 潘禮賢先生（合規主任） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 華康生物醫學控股有限公司（「本公司」），連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」））謹此宣佈張曙光先生（「張先生」）經與董事會討論後，其為投放 更多時間專注於本公司之附屬公司的業務管理而非本公司的執行職能，故已辭任本公司執行 董事（「執行董事」）；董事會主席（「董事會主席」）；提名委員會（「提名委員會」）主 席及根據香港聯合交易所有限公司（「聯交所」）GEM 證券上市規則（「GEM 上市規則」） 第 5.24 條的授權代表（「授權代表」），自二零二五年八月二十九日起生效。 張先生已經確認，彼等與董事會概無意見分歧，亦無任何與其辭任有關之其他事宜須提請本 公司股東或聯交所注意。 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 8622) (1)執行董事之辭任；(2)變更主席 ...

Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公司 (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號 : 8622 2025 INTERIM REPORT 中期報告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors sho ...

Group 1 - The core viewpoint of the article highlights Huakang Biomedical's financial performance for the six months ending June 30, 2025, showing a revenue of 12.329 million RMB, which represents a year-on-year increase of 3.4% [1] - The company reported a net loss of 2.369 million RMB, which is an increase of 33.2% compared to the previous year [1] - The basic loss per share is reported at 0.47 cents [1] Group 2 - The increase in revenue is attributed to higher sales of male infertility in vitro diagnostic reagents and a series of parasitic testing reagents during the reporting period [1]

Financial Results - Huakang Biomedical Holdings Company Limited reported its unaudited condensed consolidated financial results for the six months ending June 30, 2025[2]. - Revenue for the six months ended June 30, 2025, reached approximately RMB12.3 million, a 3.4% increase from approximately RMB11.9 million for the corresponding period[21]. - The loss for the Reporting Period was approximately RMB2.4 million, an increase of approximately RMB590,000 or 33.2% compared to approximately RMB1.8 million in the Corresponding Period, mainly due to increased administrative expenses[50]. - Basic loss per share for the Reporting Period was RMB0.47, compared to RMB0.38 for the Corresponding Period[54]. - Total comprehensive expense for the period attributable to owners of the Company was RMB2,019,000, slightly up from RMB2,015,000 in the previous year[148]. - The total comprehensive expense for the period ended June 30, 2025, was RMB(2,019,000), which includes a loss of RMB(2,369,000)[151]. - The Group recorded a gross profit of approximately RMB8.4 million for the reporting period, representing a 5.3% increase from approximately RMB8.0 million for the corresponding period[36]. - The gross profit margin increased from approximately 67.0% for the corresponding period to approximately 68.3% for the reporting period[36]. Market and Product Development - The company plans to expand its market presence and develop new products and technologies[11]. - The commercialization of semen biochemical immunoassay equipment is expected to begin in the second half of 2025, following its Class II medical device registration[22]. - The new fertility support policy issued by the PRC in October 2024 is anticipated to drive market demand growth for the Group's products[26]. - The Group aims to integrate global resources with local capabilities to expand domestic and overseas women's health markets[25]. - The Group plans to deepen technological research and development and expand its distribution network, targeting emerging markets such as Southeast Asia[31]. Corporate Governance - The board of directors collectively and individually accepts full responsibility for the accuracy and completeness of the information contained in the report[9]. - The board of directors includes both executive and non-executive members, ensuring diverse oversight[12]. - The Audit Committee consists of three independent non-executive Directors, ensuring compliance with GEM Listing Rules and CG Code[137]. - The Company has adopted a code of conduct for securities transactions by Directors, confirming full compliance during the Relevant Period[127]. - The Board is committed to high corporate governance standards, enhancing transparency and accountability[122]. Financial Position and Cash Flow - As of June 30, 2025, the Group recorded total cash and bank balances of approximately RMB36.7 million, an increase from RMB36.5 million as of December 31, 2024, primarily due to unsecured borrowing from a licensed money lender[69][71]. - The Group entered into loan agreements with a licensed money lender totaling HK$4 million, with a fixed interest rate of 9% per annum, repayable within 12 months[73][77]. - As of June 30, 2025, the unsecured borrowings and lease liabilities were approximately RMB2.3 million and RMB1.3 million respectively, resulting in a gearing ratio of approximately 7.0%, up from 2.2% as of December 31, 2024[74][76]. - The Group had 98 full-time employees as of June 30, 2025, an increase from 91 employees as of December 31, 2024[76][78]. - The company experienced a net cash inflow from financing activities of RMB1,575,000 in the first half of 2025, down from RMB6,897,000 in 2024[152]. Acquisitions and Investments - The Group completed the acquisition of Hunan Keyue Biotechnology Company Limited on June 26, 2025, to enhance its women's health market presence[25]. - The Group completed the acquisition of 91% of Keyue Bio for approximately RMB317,000 on June 26, 2025[87]. - The fair value of identifiable net assets of Keyue Bio at the acquisition date was approximately RMB349,000[200]. - The Group acquired property, plants, and equipment worth approximately RMB404,000 in 2025, up from approximately RMB301,000 in 2024, marking a growth of 34.2%[195]. Revenue and Expenses - Sales of core male fertility IVD reagents grew by 3.4% to approximately RMB9.9 million, accounting for 80.6% of the segment's total revenue[21]. - Revenue from sales of parasite antibody detection reagents rose to approximately RMB1.5 million, reflecting sustained market demand[21]. - Selling and distribution expenses decreased by approximately RMB381,000 or 9.8%, from approximately RMB3.9 million in the Corresponding Period to approximately RMB3.5 million in the Reporting Period, due to strict cost control[46]. - Administrative expenses increased significantly by approximately RMB916,000 or 21.5%, from approximately RMB4.3 million in the Corresponding Period to approximately RMB5.2 million in the Reporting Period, primarily due to professional fees for an acquisition[47]. - Research and development expenses decreased by approximately RMB159,000 or 8.0%, from approximately RMB2.0 million in the Corresponding Period to approximately RMB1.8 million in the Reporting Period[48]. Shareholding and Equity - As of June 30, 2025, Li King Yeung held 138,672,000 ordinary shares, representing 27.7% of the total shareholding[110]. - As of June 30, 2025, Yu Chi Mau held 120,752,000 ordinary shares, representing 24.1% of the total shareholding[110]. - The total number of shares in issue as of June 30, 2025, was 500,472,000[111]. - Total equity amounted to approximately RMB52.1 million as of June 30, 2025, down from approximately RMB54.0 million as of December 31, 2024[75][76]. Compliance and Regulatory Matters - The company is required to comply with the GEM Listing Rules of the Stock Exchange of Hong Kong Limited[4]. - There have been no changes in the information of Directors required to be disclosed under GEM Listing Rules during the reporting period[120]. - The Company has not purchased, sold, or redeemed any listed securities during the reporting period[119]. - No incidents of non-compliance with the Required Standard by relevant employees were noted by the Company[128].

華康生物醫學控股有限公司 (於開曼群島註冊成立之有限公司) (股份代號: 8622) 董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 華康生物醫學控股有限公司 (「本公司」) 之董事 (「董事」) 會 (「董事會」) 謹此宣佈，本 公司董事會會議將於二零二五年八月十五日 (星期五) 舉行，藉此 (其中包括) 審議及批准本 公司及其附屬公司於截至二零二五年六月三十日止六個月之未經審核簡明綜合中期業績及其 公佈，以及考慮派發中期股息（如有）及處理任何其他事項。 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 香港，二零二五年八月五日 於本公告日期，執行董事為張曙光先生、張春光先生、潘禮賢先生及張玉靜女士；非執行董 事為卜素博士及徐明博士；及獨立非執行董事為周國輝博士、王亞純女士及徐永得先生。 本公告的資料乃遵照《香港聯合交易所有限公司的 GEM 證券上市規則》而刊載，旨在提供 有 關本公司的資料；董事 ...